{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:38:29Z","timestamp":1780393109410,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":616,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1093\/annonc\/mdy056","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T12:16:00Z","timestamp":1518178560000},"page":"1266-1272","source":"Crossref","is-referenced-by-count":115,"title":["Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma"],"prefix":"10.1016","volume":"29","author":[{"given":"W.","family":"Jurczak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gaidano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Goy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Provencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Robak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Maddocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ambarkhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Winderlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dirnberger-Hertweck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Korolkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.A.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1093\/annonc\/mdy056_bb0010","doi-asserted-by":"crossref","first-page":"36.","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"10.1093\/annonc\/mdy056_bb0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1006\/smim.1998.9999","article-title":"CD19 regulates B lymphocyte responses to transmembrane signals","volume":"10","author":"Fujimoto","year":"1998","journal-title":"Semin Immunol"},{"issue":"3","key":"10.1093\/annonc\/mdy056_bb0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ejh.12427","article-title":"B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells","volume":"94","author":"Seda","year":"2015","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1093\/annonc\/mdy056_bb0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/08820130500496878","article-title":"A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry","volume":"35","author":"Olejniczak","year":"2006","journal-title":"Immunol Invest"},{"key":"10.1093\/annonc\/mdy056_bb0030","first-page":"102","article-title":"Immunophenotyping of non-Hodgkin\u2019s lymphoma. Correlation with relapse-free survival","volume":"131","author":"Schuurman","year":"1988","journal-title":"Am J Pathol"},{"issue":"20","key":"10.1093\/annonc\/mdy056_bb0035","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance","volume":"113","author":"Hiraga","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1093\/annonc\/mdy056_bb0040","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/art.37871","article-title":"CD19 is a useful B cell marker after treatment with rituximab: comment on the article by Jones et al","volume":"65","author":"Kamburova","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1093\/annonc\/mdy056_bb0045","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood-2009-06-229039","article-title":"CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody","volume":"115","author":"Awan","year":"2010","journal-title":"Blood"},{"issue":"19","key":"10.1093\/annonc\/mdy056_bb0050","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res"},{"issue":"24","key":"10.1093\/annonc\/mdy056_bb0055","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2014-08-593269","article-title":"A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL","volume":"124","author":"Woyach","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1093\/annonc\/mdy056_bb0060","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy056_bb0065","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1158\/1078-0432.CCR-13-0580","article-title":"A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"20","author":"Ribrag","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1093\/annonc\/mdy056_bb0070","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1093\/annonc\/mdy056_bb0075","first-page":"2531","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma N Engl J Med","volume":"377","author":"Neelapu","year":"2017"},{"key":"10.1093\/annonc\/mdy056_bb0080","doi-asserted-by":"crossref","first-page":"27.","DOI":"10.1002\/hon.2437_6","article-title":"Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) \u2013 an interim analysis","volume":"35","author":"Schuster","year":"2017","journal-title":"Hematol Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy056_bb0085","article-title":"CR rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001)","volume":"35","author":"Abramson","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1093\/annonc\/mdy056_bb0090","first-page":"2545","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas N Engl J Med","volume":"377","author":"Schuster","year":"2017"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy056_bb0095","article-title":"Evaluation of combination therapies with MOR00208, an Fc-enhanced humanized CD19 antibody, in models of lymphoma","volume":"30","author":"Winderlich","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdy056_bb0100","article-title":"Single-arm phase II study of MOR208 combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: L-MIND","volume":"130","author":"Salles","year":"2017","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419345302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419345302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/5\/1266\/25083206\/mdy056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:39:32Z","timestamp":1624696772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419345302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0923753419345302"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy056","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}